{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T02:44:16Z","timestamp":1766544256428},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1995,2,1]],"date-time":"1995-02-01T00:00:00Z","timestamp":791596800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Nuerosci"],"published-print":{"date-parts":[[1995,2]]},"DOI":"10.1007\/bf02190409","type":"journal-article","created":{"date-parts":[[2005,9,21]],"date-time":"2005-09-21T04:36:21Z","timestamp":1127277381000},"page":"309-316","source":"Crossref","is-referenced-by-count":7,"title":["Recent developments in the psychopharmacology of social phobia"],"prefix":"10.1007","volume":"244","author":[{"given":"Johan A.","family":"Den Boer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene M.","family":"van Vliet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman G. M.","family":"Westenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02190409_CR1","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association (DSM-III-R)","year":"1987","unstructured":"American Psychiatric Association (DSM-III-R), 3rd (1987) Diagnostic and statistical manual of mental disorders, edn, revised. American Psychiatric Association, Washington, DC","edition":"edn, revised"},{"key":"BF02190409_CR2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1192\/bjp.142.2.174","volume":"142","author":"PL Amies","year":"1983","unstructured":"Amies PL, Gelder MG, Shaw PM (1983) Social phobia: a comparative clinical study. Br J Psychiatry 142: 174\u2013179","journal-title":"Br J Psychiatry"},{"key":"BF02190409_CR3","first-page":"479","volume-title":"Anxiety and the anxiety disorders","author":"DH Barlow","year":"1985","unstructured":"Barlow DH (1985) The dimension of anxiety disorders. In: Tuma AH, Maser JD (eds) Anxiety and the anxiety disorders. Lawrence Erlbaum Associates, Hillsdale, New York, pp 479\u2013500"},{"key":"BF02190409_CR4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/030006057700500605","volume":"5","author":"G Beaumont","year":"1977","unstructured":"Beaumont G (1977) A large open multicentre trial of clomipramine in the management of phobic disorders. J Int Med Res 5: 116\u2013123","journal-title":"J Int Med Res"},{"key":"BF02190409_CR5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00004714-198602000-00022","volume":"6","author":"R Benca","year":"1986","unstructured":"Benca R, Matuzas W, Al-Sadir J (1986) Social phobia, MVP and response to imipramine \u2014 letters to the editors. J Clin Psychopharmacol 6: 50\u201351","journal-title":"J Clin Psychopharmacol"},{"key":"BF02190409_CR6","first-page":"293","volume":"4","author":"B Black","year":"1982","unstructured":"Black B, Uhde TW, Tancer ME (1982) Fluoxetine for the treatment of social phobia. J Clin Psychopharmacol 82, 4: 293\u2013295","journal-title":"J Clin Psychopharmacol 82"},{"key":"BF02190409_CR7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0002-9343(82)90592-7","volume":"72","author":"CO Brantigan","year":"1982","unstructured":"Brantigan CO, Brantigan TA, Joseph N (1982) Effect of a betablockade and beta-stimulation on stage fright. Am J Med 72: 88\u201394","journal-title":"Am J Med"},{"issue":"11 (Suppl)","key":"BF02190409_CR8","first-page":"16","volume":"52","author":"JRT Davidson","year":"1991","unstructured":"Davidson JRT, Ford SM, Smith RD, Potts NLS (1991) Long-term treatment of social phobia with clonazepam. J Clin Psychiatry 52, 11 (Suppl): 16\u201320","journal-title":"J Clin Psychiatry"},{"key":"BF02190409_CR9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/0010-440X(89)90079-5","volume":"30","author":"JA Deltito","year":"1990","unstructured":"Deltito JA, Stam M (1990) Psychopharmacology treatment of avoidant personality disorder, Compr Psychiatry 30: 498\u2013509","journal-title":"Compr Psychiatry"},{"key":"BF02190409_CR10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00004850-198801000-00005","volume":"3","author":"JA Boer Den","year":"1988","unstructured":"Den Boer JA, Westenberg HGM (1988) Effects of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3: 59\u201374","journal-title":"Int Clin Psychopharmacol"},{"key":"BF02190409_CR11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF02245749","volume":"102","author":"JA Boer Den","year":"1990","unstructured":"Den Boer JA, Westenberg HGM (1990) Serotonin function in panic disorders: a double blind placebo-controlled study with fluvoxamine and ritanserine. Psychopharmacology 102: 85\u201394","journal-title":"Psychopharmacology"},{"key":"BF02190409_CR12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/hup.470060506","volume":"6","author":"JA Boer Den","year":"1991","unstructured":"Den Boer JA, Westenberg HGM (1991) Do panic attacks reflect an abnormality in serotonin receptor subtypes? Hum Psychopharm 6: 25\u201330","journal-title":"Hum Psychopharm"},{"key":"BF02190409_CR13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0196-9781(92)90147-U","volume":"13","author":"JA Boer Den","year":"1992","unstructured":"Den Boer JA, Westenberg HGM, De Vries H (1992) The MSH\/ACTH analog ORG 2766 in anxiety disorders. Peptides 13: 109\u2013112","journal-title":"Peptides"},{"key":"BF02190409_CR14","first-page":"267","volume":"11,4","author":"NP Emmanuel","year":"1991","unstructured":"Emmanuel NP, Lydiard RB, Ballenger JC (1991) Treatment of social phobia with bupropion. J Clin Psychopharmacol 11,4: 267\u2013277","journal-title":"J Clin Psychopharmacol"},{"key":"BF02190409_CR15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00005053-198103000-00005","volume":"169","author":"IR Falloon","year":"1981","unstructured":"Falloon IR, Lloyd GG, Harpin R (1981) The treatment of social phobia. J Nerv Ment Dis 169: 180\u2013184","journal-title":"J Nerv Ment Dis"},{"key":"BF02190409_CR16","first-page":"212","volume-title":"Aging in the 1980s: selected contemporary issues in the psychology of aging","author":"SH Ferris","year":"1981","unstructured":"Ferris SH, Reisberg B, Gershon S (1981) Neuropeptide modulation of cognition and memory in humans. In: Poon L (ed) Aging in the 1980s: selected contemporary issues in the psychology of aging. American Psychology Association Washington DC, 212\u2013220"},{"key":"BF02190409_CR17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0006-8993(79)90743-1","volume":"171","author":"SE File","year":"1979","unstructured":"File SE (1979) Effects of ACTH 4-10 in the social interaction test of anxiety. Brain Res 171: 157\u2013160","journal-title":"Brain Res"},{"key":"BF02190409_CR18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0165-0270(80)90012-6","volume":"2","author":"SE File","year":"1980","unstructured":"File SE (1980) The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Methods 2: 219\u2013238","journal-title":"J Neurosci Methods"},{"key":"BF02190409_CR19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0196-9781(81)80115-5","volume":"2","author":"SE File","year":"1981","unstructured":"File SE (1981) Contrasting effects of Org 2766 and alpha-MSH on social and exploratory behavior in the rat. Peptides 2: 255\u2013260","journal-title":"Peptides"},{"key":"BF02190409_CR20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1476-5381.1978.tb07001.x","volume":"62","author":"SE File","year":"1978","unstructured":"File SE, Hyde JRG (1978) Can social interaction be used to measure anxiety? Br J Pharmacol 62: 19\u201324","journal-title":"Br J Pharmacol"},{"key":"BF02190409_CR21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.2042-7158.1978.tb13172.x","volume":"30","author":"SE File","year":"1978","unstructured":"File SE, Velluci SV (1978) Studies on the role of ACTH and 5-HT in anxiety, using an animal model. J Pharm Pharmacol 30: 105\u2013110","journal-title":"J Pharm Pharmacol"},{"key":"BF02190409_CR22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/B978-0-12-474980-1.50015-5","volume-title":"Endogenous peptides and learning and memory processes","author":"AWK Gaillard","year":"1981","unstructured":"Gaillard AWK (1981) ACTH analogs and human performance. In: Martinez JL, Jensen RA, Messing RB, Rigter H, McCaugh JL (eds) Endogenous peptides and learning and memory processes. Academic Press, New York, pp 181\u2013196"},{"key":"BF02190409_CR23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/ddr.430040209","volume":"4","author":"CR Gardner","year":"1984","unstructured":"Gardner CR, Guy AP (1984) A social interaction model of anxiety sensitive to acutely administered benzodiazepines. Drug Rev Res 4: 207\u2013216","journal-title":"Drug Rev Res"},{"key":"BF02190409_CR24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/000348948509400609","volume":"94","author":"GA Gates","year":"1985","unstructured":"Gates GA, Saegert P, Wilson N, Johnson L, Shepherd A, Hearne A, Hearne EM (1985) Effects of beta blockade on singing performance. Ann Otol Rhinol Laryngol 94: 570\u2013574","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"BF02190409_CR25","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archpsyc.1991.01810340070009","volume":"48","author":"CS Gelernter","year":"1991","unstructured":"Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ (1991) Cognitive-behavioral and pharmacological treatments of social phobia. Arch Gen Psychiatry 48: 938\u2013945","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190409_CR26","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/archpsyc.1971.01750150012002","volume":"25","author":"R Gittleman-Klein","year":"1972","unstructured":"Gittleman-Klein R, Klein D (1972) Controlled imipramine treatment in school phobia. Arch Gen Psychiatry 25: 204\u2013207","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190409_CR27","first-page":"193","volume":"156","author":"R Gittleman-Klein","year":"1973","unstructured":"Gittleman-Klein R, Klein D (1973) School phobia: diagnostic considerations in the light of imipramine effects. J Nerv Ment Dis 156: 193\u2013215","journal-title":"J Nerv Ment Dis"},{"key":"BF02190409_CR28","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/00004714-198510000-00009","volume":"5","author":"JM Gorman","year":"1985","unstructured":"Gorman JM, Liebowitz MR, Fyer AJ, Campeas R, Klein DF (1985) Treatment of social phobia with atenolol. J Clin Psychopharmacol 5: 669\u2013677","journal-title":"J Clin Psychopharmacol"},{"key":"BF02190409_CR29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0165-0327(87)90022-X","volume":"13","author":"JM Gorman","year":"1987","unstructured":"Gorman JM, Gorman LK (1987) Drug treatment of social phobia. J Affect Disord 13: 183\u2013192","journal-title":"J Affect Disord"},{"key":"BF02190409_CR30","first-page":"50","volume":"32","author":"M Gungras","year":"1977","unstructured":"Gungras M (1977) An uncontrolled trial of clomipramine in the treatment of phobic and obsessional states in general practice. J Int Med Psychol 32: 50\u201355","journal-title":"J Int Med Psychol"},{"key":"BF02190409_CR31","doi-asserted-by":"crossref","unstructured":"Haefely W, Burkard IP, Cesura AM, Kettler R, Lorez R, Martin JR, Richards JG, Scherschlicht SR (1992) Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology S6\u2013S14","DOI":"10.1007\/BF02246225"},{"key":"BF02190409_CR32","first-page":"50","volume":"6","author":"M Hamilton","year":"1967","unstructured":"Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Clin Psychol 6: 50\u201355","journal-title":"Br J Clin Psychol"},{"key":"BF02190409_CR33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1192\/bjp.142.5.512","volume":"142","author":"LR Hartley","year":"1983","unstructured":"Hartley LR, Ungapen S, Davie I, Spencer DJ (1983) The effect of beta-blocking drugs on speaker's performance and memory. Br J Psychiatry 142: 512\u2013517","journal-title":"Br J Psychiatry"},{"key":"BF02190409_CR34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-0327(87)90017-6","volume":"13","author":"PE Hayes","year":"1987","unstructured":"Hayes PE, Schulz SC (1987) LZ, Beta-blockers in anxiety disorders J Affect Disord 13: 119\u2013130","journal-title":"J Affect Disord"},{"key":"BF02190409_CR35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00004714-199306000-00003","volume":"13","author":"I Heuser","year":"1993","unstructured":"Heuser I, Heuser-Link M, Gotthardt U, Grasser A, Holsboer F (1993) Behavioral effects of a synthetic corticotropin 4\u20139 analog in patients with depression and patients with alzheimer's disease. J Clin Psychopharmacol 13: 171\u2013174","journal-title":"J Clin Psychopharmacol"},{"key":"BF02190409_CR36","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/0002-8703(84)90599-4","volume":"108","author":"IM James","year":"1984","unstructured":"James IM, Savage I (1984) Beneficial effects of nadolol on anxiety-induced disturbances of performance in musicians: a comparison with diazepam and placebo. Am Heart J 108: 1150\u20131155","journal-title":"Am Heart J"},{"key":"BF02190409_CR37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1192\/bjp.116.533.387","volume":"116","author":"D Kelly","year":"1970","unstructured":"Kelly D, Guirguis W, Frommer E, Mitchell-Heggs N, Sargant W (1970) Treatment of phobic states with antidepressants: a retrospective study of 246 patients. Br J Psychiatry 116: 387\u2013398","journal-title":"Br J Psychiatry"},{"key":"BF02190409_CR38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0165-1781(86)90123-X","volume":"19","author":"RJ King","year":"1986","unstructured":"King RJ, Mefford IN, Wang C, Murchison A, Caligari EJ, Berger PA (1986) CSF dopamine levels correlate with extraversion in depressed patients. Psychiatr Res 19: 305","journal-title":"Psychiatr Res"},{"key":"BF02190409_CR39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000414022","volume":"22","author":"MR Liebowitz","year":"1987","unstructured":"Liebowitz MR (1987) Social phobia. Mod Probl Pharmacopsychiatry 22: 141\u2013173","journal-title":"Mod Probl Pharmacopsychiatry"},{"key":"BF02190409_CR40","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archpsyc.1985.01790300097013","volume":"42","author":"MR Liebowitz","year":"1985","unstructured":"Liebowitz MR, Gorman JH, Fyer AJ, Klein DF (1985) Social phobia. Arch Gen Psychiatry 42: 729\u2013736","journal-title":"Arch Gen Psychiatry"},{"issue":"11 (Suppl)","key":"BF02190409_CR41","first-page":"10","volume":"52","author":"MR Liebowitz","year":"1991","unstructured":"Liebowitz MR, Schneier, FR, Hollander E, Welkowitz LA, Saoud JB, Feerick J, Campeas R, Fallon BA, Street L, Gittow A (1991) Treatment of social phobia with drugs other than benzodiazepines. J Clin Psychiatry 52, 11 (Suppl): 10\u201315","journal-title":"J Clin Psychiatry"},{"key":"BF02190409_CR42","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/archpsyc.49.4.290","volume":"49","author":"MR Liebowitz","year":"1992","unstructured":"Liebowitz MR, Schneier, FR, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, Klein DF (1992) Phenelzine vs Atenolol in social phobia. Arch Gen Psychiatry 49: 290\u2013300","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190409_CR43","first-page":"17","volume":"49,1","author":"RB Lydiard","year":"1988","unstructured":"Lydiard RB, Laraia MT, Howell EF, Ballenger JC (1988) Alprazolam in the treatment of social phobia. J Clin Psychiatry 49,1: 17\u201319","journal-title":"J Clin Psychiatry"},{"key":"BF02190409_CR44","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1176\/ajp.123.2.218","volume":"123","author":"M Marks","year":"1966","unstructured":"Marks M, Gelder MG (1966) Different ages of onset in varieties of phobia. Am J Psychiatry 123: 218\u2013221","journal-title":"Am J Psychiatry"},{"key":"BF02190409_CR45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1192\/bjp.131.5.486","volume":"131","author":"CQ Mountjoy","year":"1977","unstructured":"Mountjoy CQ, Roth M, Garside RF, Leitch IM (1977) A clinical trial of phenelzine in anxiety depressive and phobic neurosis. Br J Psychiatry 131: 486\u2013492","journal-title":"Br J Psychiatry"},{"issue":"5(Suppl)","key":"BF02190409_CR46","first-page":"35","volume":"51","author":"DJ Munjack","year":"1991","unstructured":"Munjack DJ, Baltazar PL, Bohn PB, Cabe DD, Appleton AA (1991) Clonazepam for the treatment of social phobia: a pilot study. J Clin Psychiatry 51, 5(Suppl): 35\u201340","journal-title":"J Clin Psychiatry"},{"key":"BF02190409_CR47","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0887-6185(91)90019-P","volume":"5","author":"DJ Munjack","year":"1991","unstructured":"Munjack DJ, Bruns J, Baltazar PL, Brown R, Leonard M, Nagy R, Koek R, Crocker B, Schafer S (1991) A pilot study of buspirone in the treatment of social phobia. J Anxiety Disord 5: 87\u201398","journal-title":"J Anxiety Disord"},{"key":"BF02190409_CR48","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/070674379003500514","volume":"35","author":"A Ontiveros","year":"1990","unstructured":"Ontiveros A, Fontaine R (1990) Social phobia and clonazepam. Can J Psychiatry 35: 439\u2013441","journal-title":"Can J Psychiatry"},{"key":"BF02190409_CR49","first-page":"733","volume":"145,6","author":"LA Papp","year":"1988","unstructured":"Papp LA, Gorman JM, Liebowitz MR, Fyer AJ, Cohen B, Klein DF (1988) Epinephrine infusions in patients with social phobia. Am J Psychiatry 145,6: 733\u2013736","journal-title":"Am J Psychiatry"},{"key":"BF02190409_CR50","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1192\/bjp.140.5.484","volume":"140","author":"JC Pecknold","year":"1982","unstructured":"Pecknold JC, McClure DJ, Appeltauer L, Allan T, Wrzesinski L (1982) Does tryptophan potentiate clomipramine in the treatment of agoraphobic and social phobia patients? Br J Psychiatry 140: 484\u2013490","journal-title":"Br J Psychiatry"},{"key":"BF02190409_CR51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000396733","volume":"8","author":"RM Pigache","year":"1981","unstructured":"Pigache RM, Rigter H (1981) Effects of peptides related to ACTH on mood and vigilance in man. Front Horm Res 8: 193\u2013207","journal-title":"Front Horm Res"},{"key":"BF02190409_CR52","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/archpsyc.1988.01800350011002","volume":"45","author":"DA Regier","year":"1988","unstructured":"Regier DA, Boyd JH, Burke JD, Rae DS, Myers JK, Kramer M, Robins LN, George LK, Karno M, Lcke BZ (1988) One-month prevalence of mental disorders in the United States: based on five epidemiological Catchment Area sites. Arch Gen Psychiatry 45: 977\u2013986","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190409_CR53","first-page":"590","volume":"145, 5","author":"J Reich","year":"1988","unstructured":"Reich J, Yates W, Tes W (1988) A pilot study of treatment of social phobia with alprazolam. Am J Psychiatry 145, 5: 590\u2013594","journal-title":"Am J Psychiatry"},{"key":"BF02190409_CR54","first-page":"470","volume":"51","author":"SR Reiter","year":"1990","unstructured":"Reiter SR, Pollack MH, Rosenbaum JF, Cohen LS (1990) Clonazepam for the treatment of social phobia. J Clin Psychiatry 51: 470\u2013472","journal-title":"J Clin Psychiatry"},{"key":"BF02190409_CR55","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/archpsyc.1987.01800210065010","volume":"44","author":"JH Riskind","year":"1987","unstructured":"Riskind JH, Beck AT, Berchik RJ, Brown G, Steer RA (1987) Reliability of DSM-II-R diagnoses for major depression and generalized anxiety disorder using the structured clinical interview for DSM-III-R. Arch Gen Psychiatry 44: 817\u2013820","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190409_CR56","first-page":"77","volume-title":"Psychopharmacology, the third generation of progress","author":"DS Robinson","year":"1987","unstructured":"Robinson DS, Kurtz NM (1987) Monoamine oxidase inhibiting drugs; pharmacological and therapeutic issues. In: Meltzer HY (ed) Psychopharmacology, the third generation of progress. Raven Press, New York, pp 77\u2013783"},{"key":"BF02190409_CR57","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00004714-199202000-00018","volume":"12","author":"FR Schneier","year":"1992","unstructured":"Schneier, FR, Chin SJ, Hollander E, Liebowitz MR (1992) Fluoxetine in social phobia (letter to the editor). J Clin Psychopharmacol 12: 62\u201363","journal-title":"J Clin Psychopharmacol"},{"key":"BF02190409_CR58","first-page":"251","volume":"13","author":"FR Schneier","year":"1993","unstructured":"Schneier FR, Saoud JB; Campeas R, Fallon BA, Hollander E, Coplan J, Liebowitz MR (1993) Buspirone in social phobia. J Clin Psychopharmacol 13: 251\u2013256","journal-title":"J Clin Psychopharmacol"},{"key":"BF02190409_CR59","first-page":"35","volume":"18","author":"L Solyom","year":"1973","unstructured":"Solyom L, Heseltine GFD, McClure DJ, Ledwidge D, Solyom C (1973) Behavioural therapy and drug therapy in the treatment of phobic neurosis. Can J Psychiatry 18: 35\u201331","journal-title":"Can J Psychiatry"},{"key":"BF02190409_CR60","first-page":"25","volume":"18","author":"L Solyom","year":"1973","unstructured":"Solyom L, Heseltine GFD, McClure DJ, Solyom C, Ledwedge B, Steinberg G (1973) Behaviour therapy vs drug therapy in the treatment of phobic neurosis. Can J Psychiatry 18: 25\u201331","journal-title":"Can J Psychiatry"},{"key":"BF02190409_CR61","first-page":"239","volume":"16","author":"C Solyom","year":"1981","unstructured":"Solyom C, Solyom L, La Pierre Y, Pecknold J, Morton L (1981) Phenelzine and exposure in the treatment of phobias. Biol Psychiatry 16: 239\u2013247","journal-title":"Biol Psychiatry"},{"key":"BF02190409_CR62","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1192\/bjp.149.4.464","volume":"149","author":"L Solyom","year":"1986","unstructured":"Solyom L, Ledwidge B, Solyom C (1986) Delineating social phobia. Br J Psychiatry 149: 464\u2013470","journal-title":"Br J Psychiatry"},{"key":"BF02190409_CR63","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00004714-199006000-00024","volume":"10","author":"H Sternack","year":"1990","unstructured":"Sternack H (1990) Fluoxetine, treatment of social phobia. J Clin Psychopharmacol 10: 230","journal-title":"J Clin Psychopharmacol"},{"key":"BF02190409_CR64","first-page":"198","volume":"19","author":"JR Tinkelberg","year":"1983","unstructured":"Tinkelberg JR, Thornton JE (1983) Neuropeptides in geriatric psychopharmacology. Psychopharmacol Bull 19: 198\u2013211","journal-title":"Psychopharmacol Bull"},{"key":"BF02190409_CR65","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1192\/bjp.127.2.163","volume":"127","author":"P Tyrer","year":"1975","unstructured":"Tyrer P, Steinberg D (1975) Symptomatic treatment of agoraphobia and social phobics: a follow-up study. Br J Psychiatry 127: 163\u2013168","journal-title":"Br J Psychiatry"},{"key":"BF02190409_CR66","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF00422146","volume":"2","author":"P Tyrer","year":"1973","unstructured":"Tyrer P, Candy J, Kelly D (1973) A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacology 2: 237\u2013254","journal-title":"Psychopharmacology"},{"key":"BF02190409_CR67","first-page":"27","volume":"54,1","author":"M Ameringen Van","year":"1993","unstructured":"Van Ameringen M, Mancini C, Streiner DL (1993) Fluoxetine efficacy in social phobia. J Clin Psychiatry 54,1: 27\u201332","journal-title":"J Clin Psychiatry"},{"key":"BF02190409_CR68","volume-title":"Handleiding bij de zelfbeoordelingsvragenlijst","author":"HM Ploeg Van der","year":"1981","unstructured":"Van der Ploeg HM, Delfares PB, Spielberger CD (1981) Handleiding bij de zelfbeoordelingsvragenlijst. Swets and Zeitlinger, Lisse"},{"key":"BF02190409_CR69","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0924-977X(92)90001-O","volume":"2","author":"HM Praag Van","year":"1992","unstructured":"Van Praag HM (1992) About the centrality of mood lowering in mood disorders. Eur Neuropsychopharmacol 2: 393\u2013404","journal-title":"Eur Neuropsychopharmacol"},{"key":"BF02190409_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-0327(87)90067-X","volume":"13","author":"HM Praag Van","year":"1987","unstructured":"Van Praag HM, Kahn RJ, Asnis GM, Wetzler S, Brown SL, Bleich A, Korn ML (1987) Denosologisation of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. J Affect Disord 13: 1\u20138","journal-title":"J Affect Disord"},{"key":"BF02190409_CR71","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0924-977X(92)90032-4","volume":"12","author":"IM Vliet Van","year":"1992","unstructured":"Van Vliet IM, Den Boer JA, Westenberg HGM (1992) Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 12: 21\u201329","journal-title":"Eur Neuropsychopharmacol"},{"key":"BF02190409_CR72","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF02244762","volume":"115","author":"IM Vliet Van","year":"1994","unstructured":"Van Vliet IM, Den Boer JA, Westenberg HGM (1994) A novel psychopharmacological approach to social phobia; a double-blind placebo-controlled study with fluvoxamine. Psychopharmacology 115: 128\u2013134","journal-title":"Psychopharmacology"},{"key":"BF02190409_CR73","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004714-198808000-00008","volume":"8","author":"M Versiani","year":"1988","unstructured":"Versiani M, Mundinn FD, Wardi AE, Liebowitz MR (1988) Tranyl cypromine in social phobia. J Clin Psychopharmacol 8: 279\u2013283","journal-title":"J Clin Psychopharmacol"},{"key":"BF02190409_CR74","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1192\/bjp.161.3.353","volume":"161","author":"M Versiani","year":"1992","unstructured":"Versiani M, Nardi AE, Mindim FD, Alves AB, Liebowitz MR, Amrein R (1992) Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 161: 353\u2013360","journal-title":"Br J Psychiatry"},{"key":"BF02190409_CR75","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0014-2999(89)90016-2","volume":"169","author":"PC Waldmeier","year":"1989","unstructured":"Waldmeier PC, Stocklin L (1989) The reversible MAO inhibitor, brofaromine, inhibits serotonin uptake in vivo. Eur J Pharmacol 169: 197\u2013204","journal-title":"Eur J Pharmacol"},{"key":"BF02190409_CR76","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/BF00647833","volume":"324","author":"PC Waldmeier","year":"1983","unstructured":"Waldmeier PC, Baumann PA (1983) A new reversible and selective inhibitor of MAO-A, on biogenic, amine levels and metabolism in rat brain. Naunyn-Schmiedebergs Arch Pharmacol 324: 20\u201326","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"BF02190409_CR77","volume-title":"Handbook of depression and anxiety","author":"HGM Westenberg","year":"1994","unstructured":"Westenberg HGM, Den Boer JA (1994) The neuropharmacology of anxiety; a review on the role of serotonin. In: Den Boer JA, Sitsen JMA (eds) Handbook of depression and anxiety. Marcel Dekker, New York"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02190409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02190409\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02190409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T17:33:37Z","timestamp":1557855217000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02190409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,2]]},"references-count":77,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1995,2]]}},"alternative-id":["BF02190409"],"URL":"https:\/\/doi.org\/10.1007\/bf02190409","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,2]]}}}